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The role of the right ventricle in pulmonary
arterial hypertension
A. Vonk Noordegraaf* and N. Galie`#
ABSTRACT: Although changes in the pulmonary vasculature are the primary cause of pulmonary
arterial hypertension (PAH), severity of symptoms and survival are strongly associated with right
ventricular function, and right heart failure is the main cause of death in patients with PAH.
Echocardiography and cardiac magnetic resonance imaging allow noninvasive evaluation of right
ventricular function and structure, and a number of indices have been shown to have potential
prognostic value in PAH. Given the importance of the right ventricle in PAH, preservation and
improvement of its function should be important aspects of therapy; however, there are currently
few data specifically related to this aspect of treatment response. Simple, reproducible,
noninvasive measures of right ventricular function would help to improve the management of
patients with PAH, and to provide tools with which to help establish the optimal therapeutic
approach to manage not only the effects of the disease on the pulmonary vasculature, but also to
support and improve right ventricular function.
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ulmonary arterial hypertension (PAH) is a
disease with a range of underlying aetiol-
ogies characterised by pathological changes
in the pulmonary arteries leading to a progressive
increase in pulmonary vascular resistance (PVR)
and pulmonary artery pressure (Ppa). Advances in
the management of patients with PAH and the
availability of disease-specific therapies have resul-
ted in improvements in morbidity and survival in
recent years [1]. Nevertheless, PAH remains a
devastating disease with progressively debilitating
symptoms and high mortality [2]. Right ventricular
failure is the main cause of death in patients with
PAH, and the ability of the right ventricle to adapt
to the progressive increase in PVR associated with
changes to the pulmonary vasculature in PAH is
the main determinant of a patient’s functional capa-
city and survival [3]. The importance of the right
ventricle in PAH has been confirmed in major
survival studies, in which a number of haemody-
namic factors directly related to right ventricle
function have been identified as significant pre-
dictors of mortality, including mean Ppa, right atrial
pressure, cardiac output and cardiac index [2, 4, 5].
Despite its importance, until relatively recently the
right heart has not received the same degree of
research interest as other aspects of PAH, and
relatively little is known about the mechanisms of
right ventricular failure in PAH, the prognostic
implications of specific changes in right ventricu-
lar structure and function, or the effects of current
PAH-specific therapies on the right ventricle [6–8].
The establishment of indicators of right ventricu-
lar function and structure, in particular those
measured noninvasively, that could be used to
assess prognosis and response to therapy would
provide useful tools for further research, as well
as for patient management. Currently, the most
widely used noninvasive techniques are echocar-
diography (ECHO) and cardiac magnetic reso-
nance imaging (CMRI), and a number of potential
indicators assessed using these methods have
been proposed. However, many of these indica-
tors remain to be fully validated and standar-
dised in patients with PAH. In terms of treatment,
current PAH-specific therapies target pathways
known to be involved in the pathogenesis of the
pulmonary vascular changes of the disease, but
little attention has been given to the effects of
treatment on the right ventricle.
This article reviews the effects of PAH on the
right ventricle, the role of ECHO and CMRI, the
prognostic value of noninvasive markers of right
ventricular structure and function, and available
data on the effects of PAH-specific therapies on
the right ventricle.
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THE RIGHT VENTRICLE IN PAH
PAH can arise sporadically (idiopathic PAH; IPAH), can be
heritable, or can be related to risk factors or associated condi-
tions, such as connective tissue disease, congenital systemic-to-
pulmonary shunts, portal hypertension, drugs and toxins, and
HIV infection [9]. However, despite heterogeneous underlying
aetiologies, all forms of PAH share similar clinical and
haemodynamic findings and identical pathological changes in
the pulmonary vasculature. These changes are characterised by
remodelling of small pulmonary arteries (,500 mm diameter)
due to the proliferation of smooth muscle and endothelial
cells, leading to hypertrophy of the media and intima, and the
formation of plexiform lesions [10, 11]. Although a number of
underlying mechanisms for these changes have been proposed,
the pathophysiology of PAH is not clearly understood. Whatever
the underlying causes, narrowing of the pulmonary vessels,
together with the presence of in situ thrombosis and, to a greater
or lesser degree, vasoconstriction, leads to restrictions in pulmo-
nary blood flow, and characteristic progressive elevations in PVR
and Ppa.
Increased afterload is the primary cause of right ventricular
adaptation and, ultimately, failure in PAH. The anatomical
characteristics of the normal right ventricle (thinner wall and
crescent shape) means that it has greater compliance than the
left ventricle and is generally able to adapt rapidly to changes
in volume load [3]. In the normal heart, a pressure–volume
relationship exists in which the right ventricle adapts to an
increase in load with an increase in contractility. In patients with
PAH, the right ventricle initially copes with the increase in
afterload caused by increasing PVR and decreasing pulmonary
vascular compliance with initially enhanced systolic contrac-
tion; at this stage there is concentric remodelling of the right
ventricle, and right atrial pressure remains normal with a steep
increase in mean Ppa, and maintenance of cardiac index [12].
Structurally, rising systolic and diastolic ventricular pressures
increase diastolic and systolic stretch on the right ventricular
wall, which leads initially to an increase in muscle mass
(adaptive hypertrophy) due to increased protein synthesis and
an increase in cardiomyocyte size through the addition of
sarcomeres [7]. However, the right ventricle cannot maintain
adaptive hypertrophy in the face of sustained pressure over-
load, and eventually there is a transition to dilatation. At this
stage there is no further increase, or even a decrease, in right
ventricular contractility, despite a further increase in load (so
called ‘‘uncoupling’’ of the right ventricle). The mechanisms
which halt further adaptation of the right ventricle are poorly
understood, although there is increasing evidence that an
oxygen supply/demand dysbalance for the right ventricle plays
an important role in this process [13], resulting in a complex
series of changes in cardiomyocytes and their extracellular
matrix [7]. One consequence of right ventricular dilatation is an
increase in wall tension, which increases myocardial oxygen
demand and simultaneously decreases right ventricular perfu-
sion, leading to further compromised contractility and dilata-
tion. Other factors have also been implicated in the progressive
decline of contractility and of right ventricular failure in PAH,
including increased chronic sympathetic activation [14, 15],
oxidative and nitrosative stress, immune activation and cardio-
myocyte apoptosis [7]. An increase in ventricular volume may
also lead to functional tricuspid regurgitation, caused by
annular valve dilatation and chordal traction, which in turn
results in right ventricular volume overload, and thus further
progressive annular dilation and right ventricle remodelling
[16]. As right ventricular function declines, an increase in right
ventricular contraction time and subsequent ventricular asyn-
chrony, together with a decrease in right ventricular stroke
volume, leads to underfilling of the left ventricle [17–19]. Filling
of the left ventricle is also impaired due to the development of
leftwards ventricular septal bowing, resulting from prolonged
right ventricular contraction time reducing left ventricle volume
during early diastole [18–20]. This, together with systolic/
diastolic right ventricular dysfunction, contributes to the marked
decline in cardiac output seen in severe PAH. Once right
ventricular function has declined, a vicious circle of events is
underway which, if not interrupted, subsequently leads to right
heart failure.
PROGNOSTIC VALUE OF NONINVASIVE MEASURES OF
RIGHT VENTRICULAR STRUCTURE AND FUNCTION
The importance of the progression of right ventricular failure
on the outcome of patients with PAH is confirmed by the
prognostic impact of measures of right ventricular pump func-
tion, such as right atrial pressure, cardiac index and Ppa [5].
In treatment guidelines, cardiac index and right atrial pressure
are recommended as important prognostic measures for the
evaluation of disease severity and response to treatment [1].
Right heart catheterisation (RHC) is considered the ‘‘gold
standard’’ measurement technique for such haemodynamic
variables and is accepted as essential for the confirmation of
PAH [1]. Although the incidence of complications is low when
performed in experienced centres [21], RHC is associated with
a small but real risk of morbidity (e.g. haematoma and pneu-
mothorax) and mortality, which limits its use as a regular follow-
up tool to monitor patient status over time or during treatment.
This has raised interest in the ability of noninvasive measures
to assess patients, to provide prognostic information, and to
perform serial measurements to evaluate response to therapy. Of
these, the two most widely used techniques are ECHO and
CMRI. Although both methods provide variables that correlate
with RHC-determined haemodynamic measures linked with
prognosis (e.g. Ppa estimation based on ECHO-derived peak
velocity of the jet of tricuspid regurgitation; cardiac output based
on stroke volume by CMRI), they also offer a range of additional
functional and anatomical measures, including those related to
the right heart and right ventricular function.
Echocardiographic prognostic indicators in PAH
ECHO is widely used as part of the initial assessment of
patients in whom there is a suspicion of PAH, in the screening
of high-risk patients and during follow-up [1, 22].
In total, over 20 different ECHO parameters of right ventricular
morphology and function have been identified [23], although to
date only a few have been reported to be associated with
prognosis in PAH (table 1). The most reported prognostic
association with mortality is the presence of pericardial effusion
on ECHO. Pericardial effusion was reported in 54% of patients
with severe IPAH, with larger effusion being associated with
haemodynamic and echocardiographic evidence of right heart
failure, impaired exercise tolerance and poor 1-yr prognosis
[36]. In a prospective, multicentre ECHO study of 81 patients
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with PAH, the presence of a pericardial effusion was the
strongest predictor of mortality over the follow-up period of
36.9¡15.4 months on multivariate analysis and, together with
right atrial area and diastolic eccentricity index (a measure of left
septal shift), was also predictive of a composite end-point of
death or transplantation (fig. 1) [25]. More recently, data from
the large REVEAL registry [4] and from a cohort study of 276
Chinese patients with PAH also demonstrated that the presence
of pericardial effusion was an independent predictor of morta-
lity [24]. The cause of pericardial effusion in PAH is linked to
increased right atrial pressure which impairs venous and
lymphatic drainage of the myocardium and is, therefore, a
reflection of right ventricular (diastolic) dysfunction [25, 26].
Although clearly of value as a prognostic indicator, the degree
of pericardial effusion that should be considered to be signifi-
cant remains to be defined. In general, studies including this
parameter give no formal criteria and do not specify factors such
as effusion size and the phase at which it should be measured.
Along with the presence of pericardial effusion, the tricuspid
annular plane systolic excursion (TAPSE) is recommended by
treatment guidelines as a prognostic indicator in PAH for the
TABLE 1 Prognostic value of right heart parameters in pulmonary arterial hypertension: echocardiography
Parameter Correlation Study design First author [ref.]
Pericardial effusion Mortality Retrospective, multi-
centre; n5276
ZHANG [24]
Mortality Registry data;
n52716
BENZA [4]
Mortality; combined end-point
death/transplantation
Prospective, multi-
centre; n581
RAYMOND [25]
Right ventricular failure; exercise
tolerance; poor prognosis
Single centre;
n579
HINDERLITER [26]
Right atrial size Mortality; transplantation Prospective, single
centre; n525
BUSTAMANTE-LABARTA [27]
Right atrial indexed area Mortality Prospective, multi-
centre; n581
RAYMOND [25]
Right ventricular diameter Mortality Prospective, single
centre; n572
GHIO [28]
Right ventricular fractional area change Mortality Prospective, single
centre; n559
GHIO [29]
TAPSE Survival Prospective, single
centre; n559
GHIO [29]
Right ventricular function;
survival
Prospective, single
centre; n547
FORFIA [30]
Right ventricular myocardial performance (Tei) index Cardiac death/transplantation Retrospective, single
centre; n553
YEO [31]
Degree of pulmonary regurgitation;
left ventricular eccentricity index;
presence of pericardial effusion
Retrospective, single
centre; n593
GRAPSA [32]
Tricuspid valve regurgitation Survival Prospective, single
centre; n559
GHIO [29]
Mortality; transplantation Prospective, single
centre; n525
BUSTAMANTE-LABARTA [27]
Eccentricity Survival Prospective, single
centre; n559
GHIO [29]
Composite end-point of
death/transplantation
Prospective, multi-
centre; n581
RAYMOND [25]
Right ventricular free wall systolic strain Disease severity, disease
progression and mortality
Prospective, single
centre; n580
SACHDEV [33]
Right ventricular dyssynchrony WHO FC; eccentricity index;
hospitalisations due to
PH/heart failure
Prospective, single
centre; n552
LO´PEZ-CANDALES [34]
Right ventricular systolic to diastolic duration ratio Clinical outcomes; 6MWD; death
or transplantation; right ventricular
fractional area of change
Retrospective, single
centre; n547
ALKON [35]
TAPSE: tricuspid annular plane systolic excursion; WHO FC: World Health Organization functional class; PH: pulmonary hypertension; 6MWD: 6-min walk distance.
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assessment of disease severity and response to therapy, largely
because both parameters can be assessed in the majority of
patients [1]. TAPSE is a relatively simple measure of the
longitudinal movement of the lateral tricuspid annulus towards
the right ventricular apex. It is used as a correlate of right
ventricular systolic function, as the longitudinal displacement of
the right ventricular base accounts for the greater proportion of
total right ventricular volume change in comparison with radial
shortening in normal ventricles. TAPSE has been shown to have
a reasonable correlation with right ventricular ejection fraction
(RVEF) [6, 37]. In terms of prognostic value, compared with a
TAPSE of o1.8 cm, TAPSE of ,1.8 cm in patients with PAH
was shown to be associated with greater right ventricular
systolic dysfunction (lower cardiac index and right ventricular
percentage area change) and right heart remodelling (measured
by right atrial area index), and decreased survival (94 and 88%
versus 60 and 50% at 1 and 2 yrs, respectively; hazard ratio 5.7,
95% CI 1.3–24.9; p50.02) [30]. However, there are limitations to
TAPSE, particularly in patients with significant tricuspid
regurgitation [38], or where left ventricular function, which
can also influence TAPSE, is impaired [39].
Parameters of right heart morphology (atrial and ventricular)
have also been linked to mortality in studies using ECHO
(table 1). GHIO et al. [28] performed an ECHO assessment of 72
patients with IPAH and found that mortality was higher in
patients with a right ventricular diameter .36.5 mm than in
patients with a right ventricular diameter f36.5 mm: 15.9 (95%
CI 9.4–26.8) versus 6.6 (95% CI 3.3–13.2) events per 100 person-
yrs (p50.0442). Mortality was similar in patients with right
ventricular wall thickness above or below the median value
(6.6 mm). However, a right ventricular diameter .36.5 mm in
conjunction with a right ventricular wall thickness .6.6 mm
was not associated with a poorer prognosis (p50.6837). These
data suggest that a larger right ventricular diameter is a marker
of a poor prognosis but a greater right ventricular wall thickness
reduces the risk of death associated with a dilated right ventricle
[28], which can be explained by the fact that increased right
ventricular wall thickness in case of dilatation protects the
ventricle from abnormally high wall tension. The complex
anatomy of the right ventricle means that accurate measurement
of factors such as size or volume using two-dimensional
imaging can be complicated, and also that some measurements
that rely on geometric assumptions can be difficult to adopt for
the right ventricle by ECHO.
The myocardial performance or Tei index (isovolumic con-
traction time plus isovolumic relaxation time divided by
ejection time) represents an estimate of global right ventricular
performance which is unaffected by right ventricular geometry
[40]. The Tei index increases with increasing right ventricular
dysfunction, and has been shown to have prognostic value in a
range of conditions, including PAH [31, 32]. Limitations of the
Tei index, however, include the fact that it is highly sensitive to
the volume status of the patient, and that the parameter is less
reliable during tachycardia. Other reported ECHO prognostic
parameters include eccentricity index [25], right ventricular
dyssynchrony [34] and right ventricular systolic to diastolic
duration ratio [35]. A comprehensive assessment of prognosis
is likely to require the evaluation of a number of different
ECHO parameters. A comparative evaluation of the prognostic
value of a number of right ventricular function indices in 59
patients with IPAH found that those with TAPSE f15 mm
and left ventricular eccentricity index o1.7 had the highest
rate of death or transplantation (51.7 per 100 person-yrs), while
patients with TAPSE .15 mm and mild or no tricuspid
regurgitation had the lowest event rate (2.6 per 100 person-
yrs) [29]. With the development of newer echocardiographic
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FIGURE 1. Kaplan–Meier survival curves for echocardiographic predictors of outcomes. Reproduced from [25] with permission from the publisher.
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technologies, and methods such as real-time three-dimensional
ECHO and speckle-tracking ECHO, there have been a number
of studies investigating novel indices of right ventricular
dimensions and function in PAH [41, 42]. Their prognostic
values require further investigation and validation.
Echocardiography is a well-established technique that is widely
available, inexpensive and safe, and has proven value in the
screening and management of patients with PAH. Nevertheless,
it is associated with a number of technical drawbacks and limit-
ations. The technique is operator-dependent, relying on the
training and experience of the sonographer. In addition, imaging
may be difficult in some clinical situations (e.g. emphysema) and
factors associated with the body habitus may affect the acoustic
window and thus the ability to visualise and/or measure certain
parameters (e.g. tricuspid regurgitation) in some patients. ECHO
measurements are highly dependent on factors such as image
quality, insonation angle, and load, respiratory phase and probe
or patient position during examination, which can introduce
inaccuracy and variability, particularly in patients with mild
right ventricular abnormalities [6]. In addition, progressive right
ventricular dilatation is also accompanied by changes in heart
position and orientation which can impact on the interpretation
of serial measurements [6]. There is also a lack of standardised
models for the calculation of right ventricular volumes and
ejection fraction. Addressing these factors is particularly impor-
tant as ECHO becomes more widely used in routine clinical
practice in PAH, outside of more controlled research protocols.
Despite these limitations, ECHO is likely to remain an important
method for the screening, diagnosis and management of patients
with PAH, given its widespread availability. In addition, the
development and validation of new techniques and methods
may help address many of these current restrictions [43, 44].
CMRI prognostic indicators in PAH
Based on current data, CMRI is not a suitable tool for the
diagnosis of PAH; however, its ability to provide a more com-
plete overall picture of right ventricular structure and function
than RHC and ECHO means that it is proving to be a valuable
tool for the assessment of the right ventricle in PAH, particularly
its response to therapy [43, 45]. There have been fewer studies
evaluating the prognostic value of CMRI parameters in PAH
than studies assessing ECHO parameters (table 2). In a study of
64 patients with IPAH followed for 1 yr, right ventricular
dilatation and low stroke volume, along with RVEF measured
using CMRI were found to be prognostic of mortality (fig. 2) [48].
This study also found that an on-treatment decline in stroke
volume was related to treatment failure. Ventricular mass
measured by CMRI has been shown to correlate with survival:
1- and 2-yr survival was 91% for patients with a ventricular mass
index (VMI; ratio of the right and left ventricular end diastolic
mass) ,0.7 compared with 65 and 43% in patients with a VMI
o0.7 [46], and an elevated right ventricular mass was predictive
of poor outcome in a study of 73 patients with PAH [47].
As a technique, CMRI has a number of benefits over ECHO.
CMRI provides a higher spatial resolution, and is not limited
by factors affecting ECHO (e.g. acoustic window). CMRI
allows for the visualisation and measurement of complex three-
dimensional geometry and it is therefore particularly suited to the
complex morphology of the right ventricle. Precise, noninvasive
assessment of cardiac volumes and function is possible, without
the need for geometric approximations, while assessments such
as flow measurements in the heart and great vessels using tech-
niques such as cine phase-contrast provide more comprehensive
data on cardiac function than ECHO [43, 50, 51]. However, in
comparison with ECHO, CMRI is expensive and not widely
available. Data acquisition and analysis tends to be more inten-
sive and time consuming, and demands significant technical
support and expertise. The need for breath holding may be a
problem in patients with PAH and claustrophobia when using
smaller diameter magnets can be problematic for some, although
these problems are decreasing with improving technology. In
addition, the use of magnetic resonance imaging is incompatible
with ferromagnetic objects such as pacemakers and defibrillators,
and infusion pumps, which could also limit its use in some
patients [43, 50, 51].
To date, the majority of data regarding the prognostic value of
ECHO and CMRI parameters have come from small, single-
centre studies; such centres are generally highly experienced
and, given the operator dependency of the techniques, it is
unclear how appropriate these parameters might be in routine
practice. Due to the small size of these studies, multivariate
analysis is not possible; therefore, there are limited data on the
correlation between these measures and other clinical para-
meters. There is a need for more multicentre studies to confirm
the value of these measures.
TABLE 2 Prognostic value of right ventricular parameters in pulmonary arterial hypertension (PAH): cardiac magnetic
resonance imaging
Parameter Correlation Study design First author [ref.]
Ventricular mass index Survival Prospective, single centre; n540
overall, n528 with PAH at rest
HAGGER [46]
Indexed right ventricular mass Mortality Prospective, single centre; n574 BRADLOW [47]
Right ventricular dilatation Mortality Prospective, multicentre; n564 VAN WOLFEREN [48]
Stroke volume Mortality Prospective, multicentre; n564 VAN WOLFEREN [48]
RVEF Mortality Prospective, multicentre; n564 VAN WOLFEREN [48]
Myocardial fibrosis (late gadolinium
enhancement)/RVEF
Major adverse clinical events (hospitalisation,
death and referral/need for lung transplantation)
Retrospective, single centre; n521 SOMA [49]
RVEF: right ventricular ejection fraction.
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EFFECT OF PAH-SPECIFIC THERAPIES ON THE RIGHT
VENTRICLE
Current PAH-specific therapies (prostacyclins, endothelin
receptor antagonists (ERAs) and phosphodiesterase (PDE)-5
inhibitors) target the pathways involved in the vascular
remodelling and abnormal vasoreactivity in the pulmonary
vasculature, resulting in a reduction in PVR [10]. In the early
stages of PAH, where right ventricular function and cardiac
output is relatively well preserved, such a reduction in PVR
results in a decrease in mean Ppa consequently resulting in a
reduction of right ventricular power output, which is the
product of cardiac output and Ppa. However, in patients with
severe PAH, a decrease in PVR resulting from medication will
be followed by an increase in cardiac output rather than a
decrease in Ppa, resulting in an unchanged power output [12].
For this reason, a particular reduction in PVR may have a
beneficial effect on the right ventricle in milder forms of PAH,
but may not have a beneficial effect on the right ventricle in
severe PAH. The latter explains why progressive right
ventricular function loss can be found in patients with severe
PAH who respond to therapy by a decrease in PVR.
Although evidence from patients who have undergone lung
transplantation or pulmonary endarterectomy has demon-
strated that PAH-induced right ventricle remodelling is
reversible [52–54], there are few data on the direct effects of
PAH-specific therapies. Such therapies may affect the right
ventricle via direct cardiac-specific effects or indirect effects by
reducing right ventricular load. In a recent meta-analysis of
clinical studies of PAH-specific therapies, active treatment was
associated with a reduction in PVR which was accompanied by
a decrease in Ppa and an increase in stroke volume, but without
an increase in contractility (fig. 3), suggesting that current PAH
therapies have predominantly pulmonary vasodilating effects
and have limited cardiac-specific effects [12].
The establishment of suitable ECHO and CMRI parameters to
predict outcome and for the serial assessment of response to
therapy would be useful management tools; however, to date
there are very few randomised, controlled studies of PAH-
specific therapies which include the assessment of such parame-
ters as outcome measures (table 3). The most comprehensive
assessment published to date is an ECHO substudy of patients
included in the pivotal BREATHE-1 study of bosentan (a dual
ERA) in patients with PAH [55]. Compared with placebo, treat-
ment with bosentan for 16 weeks resulted in significant improve-
ments in Doppler-derived cardiac index (+0.4 L?min-1?m-2; p5
0.007), left ventricular early diastolic filling velocity (+10.5 cm?s-1;
p50.003), left ventricular end-diastolic area (+4.2 cm2; p50.003),
left ventricular systolic eccentricity index (-0.12; p50.047), right
ventricular end-systolic area (-2.3 cm2; p50.057), right:left ven-
tricular diastolic areas ratio (-0.64; p50.007), Doppler right
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FIGURE 2. Kaplan–Meier survival curves for baseline cardiac magnetic resonance imaging variables according to the median value in patients with pulmonary
hypertension. SVI: stroke volume index; RV: right ventricular; RVEDVI: RV end-diastolic volume index; LVEDVI: left ventricular end-diastolic volume index. Reproduced from
[48] with permission from the publisher.
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ventricular index (-0.06; p50.03) and percentage of patients with
an improvement in pericardial effusion score (17%; p50.05).
These findings reflect the improved exercise capacity and
decreased risk of clinical worsening seen in patients treated
with bosentan in BREATHE-1 [57]. In a study of epoprostenol
therapy, beneficial effects on right ventricular structure and
function (right ventricular dilatation, curvature of the interven-
tricular septum and maximal tricuspid regurgitant jet velocity)
compared with placebo were reported following 12 weeks of
treatment, with change in 6-min walk distance (6MWD) between
baseline and 12 weeks being inversely related to the change in
diastolic eccentricity index and pericardial effusion size [36].
Such improvements may contribute to the clinical improvement
and prolonged survival observed with epoprostenol in other
studies [58, 59].
Other evidence of improvements in right ventricular para-
meters has come from descriptive studies using a number of
PAH-specific therapies; however, these generally include a
small number of patients, and this, together with the fact that
such studies evaluated different parameters (both in terms of
functional parameters and measures of right ventricular size/
mass), makes the assessment of results difficult. In general,
right ventricular parameters such as Tei index, RVEF and right
ventricular size have shown improvement following PAH-
specific therapy, although results for individual parameters
and different therapies vary (table 4). Reductions from baseline
in right ventricular size or mass have been reported following
therapy with bosentan alone [62], and in combination with
sildenafil (PDE-5 inhibitor) [48, 56]. No positive effects on right
TABLE 3 Right ventricular response to therapy: randomised studies
First author [ref.] Patients Therapy NYHA/WHO FC at
initiation of therapy
I/II/II/IV %
Treatment
length
Positive parameters versus placebo
Prospective, multicentre studies
Echocardiography
GALIE [55] IPAH or PAH-CTD
(n585); bosentan
(n556) or placebo
(n529)
Bosentan 0/0/84/16 16 weeks Lower increase in right ventricular area and less
worsening of right ventricular per cent area
compared with placebo
Treatment improved right:left ventricular diastolic
areas ratio, increased right ventricular ejection
time, stroke volume and cardiac index,
and improved Doppler right ventricular index
Trend towards a reduction of maximal TRV
HINDERLITER [36] Severe IPAH (n581;
n541 treated with
prostacyclin)
Epoprostenol 0/0/74/26 12 weeks Beneficial effects on right ventricular size,
curvature of the interventricular septum
and maximal TRV
No significant effects of treatment on right ventricular
per cent change in area or pericardial effusion size
MRI
WILKINS [56] PAH (n542) Simvastatin add-
on therapy
0/0/52/48 6–12 months Significant decrease in right ventricular mass over
the first 6-month period; no significant changes
in RVEF or Tei index, or right ventricular systolic
pressure as estimated by echocardiography
At 12 months, the decrease in right ventricular
mass seen on active treatment appeared to have
reversed in those who continued on simvastatin
NYHA/WHO FC: New York Heart Association/World Health Organization functional class; MRI: magnetic resonance imaging; PAH: pulmonary arterial hypertension; IPAH:
idiopathic PAH; PAH-CTD: PAH associated with connective tissue disease; TRV: tricuspid regurgitant velocity; RVEF: right ventricular ejection fraction.
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FIGURE 3. Meta-analysis of pulmonary arterial hypertension trials by pump
function. DSVI: change in indexed stroke volume; DP¯pa: change in mean pulmonary
arterial pressure; PVR: pulmonary vascular resistance. Reproduced from [12] with
permission.
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TABLE 4 Right ventricular response to therapy: descriptive studies
First author [ref.] Patients Therapy NYHA/WHO FC
at initiation
of therapy
I/II/II/IV %
Treatment length Main right ventricle-related findings and associations
Prospective, multicentre studies
Echocardiography
KEOGH [60] PAH (various);
n5112
Combination therapy
(ERAs/sildenafil/iloprost)
0/13/61/26 Mean 7.9¡5.6
months
Improvements in right ventricular systolic function and
severity of tricuspid regurgitation on sequential measurement
SOHN [61] PAH (various);
n512
Bosentan 0/0/100/0 12 weeks Trend towards decrease in right ventricular end-systolic
and end-diastolic areas, and in cardiac index
Significant reduction in maximum TRV
SITBON [62] Severe PAH
associated with
HIV infection;
n516
Bosentan 0/0/94/6 16 weeks Significant decrease in right ventricular area, right
ventricular end systolic area, AcT/RVET and end systolic
eccentricity index
Improvements in Tei index
Prospective, single-centre studies
Echocardiography
DUFFELS [63] PAH-CHD; n59
CTEPH; n59
Bosentan 0/11/89/0 1 yr Responders (n512) showed significant improvements in right
ventricular end diastolic area index, and TVI RVOT index,
and improvements in right ventricular early diastolic filling,
right ventricular contraction time and Tei index
LAMMERS [64] Children;
n539
Epoprostenol 0/0/69/31 Mean 27¡21
months
No significant improvement in right ventricular hypertrophy or strain
Improvements in right ventricular function (semi-quantitative
assessment) in some patients
RUIZ [65] Severe PAH;
n520
Sildenafil rescue
therapy
Significant reduction of right ventricular end-diastolic diameter
and left ventricular diastolic eccentricity index with treatment
DYER [66] Children, IPAH; n512 Bosentan Not given Median 9 (3–19) months Tei index decreased significantly in responders to therapy
ALLANORE [67] SSc with normal Ppa;
n518
Bosentan Not given 4 weeks Significant improvement in peak systolic and diastolic strain rate
SEYFARTH [68] Progressive PAH
despite prostanoid
therapy; n516
Bosentan rescue
therapy
0/37/50/13 Mean 13.5¡5.0
months
Tei index improved from baseline at 6 months and last follow-up
SEBBAG [69] IPAH; n516 Epoprostenol 0/0/37.5/62.5 Mean 5.9¡4.6
months
Significant improvement in Tei index
No significant change in right ventricular size, TRV, cardiac
output or heart rate
Improvements in Tei index related to clinical improvements
CMRI
CHIN [70] PAH (unspecified);
n516
Bosentan 12 months Trend toward improvement in right ventricular stroke, but no change
in RVEF or right ventricular end-diastolic volume following treatment
6MWD improved more in patients in whom RVEF increased
Patients who died during follow-up had
significantly lower RVEF and left ventricular end-diastolic
volume indexes than surviving patients
VAN WOLFEREN [71] PAH; n515 Bosentan/sildenafil
combination therapy
0/13/87/0 12 months bosentan mono-
therapy followed by 3 months
combination therapy
Significant decrease in right ventricular mass and RVEF
Improvement in right ventricular end diastolic volume
ALLANORE [67] SSc with normal
Ppa; n518
Bosentan Not given 4 weeks Significant improvement in myocardial perfusion index
WILKINS [56] PAH (various);
n526
Bosentan alone (n513)
or in combination with
sildenafil (n513)
0/0/100/0 16 weeks Reduction in right ventricular mass from baseline in patients
who completed combination therapy regimen
Significant increase in cardiac index associated with
significant reduction in eccentricity index during systole
in patients treated with combination therapy
No change in Tei index
ROELEVELD [72] IPAH; n511 Epoprostenol 0/0/64/36 1 yr Significant improvement in stroke volume associated with
significant improvement in cardiac output measured by CMRI
Right ventricular dilatation and hypertrophy were not
reversed by epoprostenol therapy, but did not progress
Retrospective, single-centre
studies
Echocardiography
BASIL [73] PAH; n517 Not given Not given 6 months Serial improvements in TAPSE are paralleled by
improving 6MWD and falling BNP levels
NATH [74] PAH; n520 Epoprostenol Mean 22.7¡9.3 months Peak TRV and Ppa/PVVTI were significantly improved
during treatment
No significant change in Tei index
CMRI
BLALOCK [75] PAH (predominantly
IPAH); n512
Ambrisentan 0/0/100/0 1 and 2 yrs No significant change from baseline in right and left
ventricular volumes and function after 1 yr
Statistically significant improvement in RVEF at 2 yrs
compared with baseline, but no significant change in
the indexed right ventricular mass or end-diastolic volume
MICHELAKIS [76] PAH; n55; n53
underwent MRI
Sildenafil Not available 3 months Reduction in right ventricular mass
RVEF improved and abnormal septal shift to left
ventricle was reversed
NYHA/WHO FC: New York Heart Association/World Health Organization functional class; MRI: magnetic resonance imaging; CMRI: cardiac MRI; PAH: pulmonary arterial hypertension; ERA: endothelin
receptor antagonist; TRV: tricuspid regurgitant velocity; AcT: acceleration time; RVET: right ventricular ejection time; PAH-CHD: PAH associated with congenital heart disease; CTEPH: chronic
thromboembolic pulmonary hypertension; TVI RVOT: tricuspid regurgitant velocity right ventricular outflow time-velocity integral; IPAH: idiopathic PAH; SSc: systemic sclerosis; Ppa: pulmonary artery
pressure; RVEF: right ventricular ejection fraction; 6MWD: 6-min walk distance; TAPSE: tricuspid annular plane systolic excursion; BNP: brain natriuretic protein; PVVTI: pulmonary valve velocity time integral.
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ventricular mass were reported following long-term therapy
with ambrisentan [75]. In contrast with the short-term,
randomised study mentioned above, longer term studies of
epoprostenol have not shown a positive treatment effect on
right ventricular size/mass [64, 69, 72], although without a
comparator arm it is not possible to determine whether
long-term therapy slowed down the rate of right ventricular
hypertrophy or dilatation. Overall, therefore, the effects of
PAH-specific therapies on right ventricular function remain to
be fully investigated, although the results above show that
parameters predictive of prognosis at baseline do not
necessarily predict prognosis if measured as a change over
time when the patient is treated medically.
Importantly, although current treatments reduce right ventri-
cular load, they do not reduce right ventricular power output or
pressure significantly [12], and so right ventricular failure may
continue to progress in a subgroup of patients, especially those
with severely compromised haemodynamics at baseline. There-
fore, diagnosis and active management of patients with less
advanced disease (and relatively preserved right ventricular
function) may improve outcome [2]. Evidence that this may be
the case comes from the EARLY study of bosentan in mildly
symptomatic PAH, which showed improvements in prognos-
tic indicators such as PVR and 6MWD, as well as delayed time
to clinical worsening in the treatment group compared with
placebo [77]. With respect to the effect on the right ventricle,
treating the patient when they have little clinical and haemo-
dynamic impairment (i.e. in functional class II), the magnitude
of the decrease in PVR and mean Ppa achievable using current
PAH-specific therapies is likely to have a more favourable effect
on reducing stroke volume and the work performed by the right
ventricle than in patients with more severe disease, in whom a
greater reduction in PVR/mean Ppa is required to bring about a
similar decrease in right ventricular workload. However, given
the fact that most patients with PAH are not diagnosed until
they are in functional class III or IV, additional strategies to
preserve the right ventricle are required [12], as is the devel-
opment of therapies and strategies that specifically target and
support the right ventricle [78].
CONCLUSIONS
The response of the right ventricle to the increase in afterload
produced by the pulmonary vascular changes characteristic of
PAH is the key factor in the development of symptoms and in
determining survival. Despite its prognostic importance, the
right ventricle has been less investigated in PAH than the
pulmonary vasculature, and currently there is a lack of long-
term data on the prognostic value of right ventricle parameters
and on the effects of PAH-specific therapies on the right
ventricle.
The identification of risk factors or indicators related to the
right ventricle that are relevant at baseline and during
treatment, and which can be assessed regularly, and preferably
noninvasively, will allow the comprehensive assessment of
disease severity and response to therapy. ECHO and CMRI are
being used increasingly in this respect, although, as well as
undoubted benefits, both techniques currently have a number
of limitations, and data from studies of the value of these
techniques in prognosis and response to therapy are limited.
However, with further research, validation and standardisa-
tion, and continuing improvements in technology and method-
ology, it is possible that ECHO and CMRI (alone and in
combination) will largely supplant invasive techniques such as
RHC for the evaluation of the right ventricle in patients with
PAH in the future [41]. Given the central role that right
ventricular failure plays in PAH and the fact that, despite
improvements in survival, right ventricular failure remains the
most common cause of death in patients with PAH, greater
consideration to the development of means for assessing the
presence and extent of right ventricular failure, both sub-
clinical and overt, and strategies to support the right ventricle
in PAH are required.
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